Autolus Therapeutics plc announced that the US FDA has granted RMAT designation to its lead gene therapy obecabatagene autoleucel, a CD19-directed autologous chimeric antigen receptor (CAR) T therapy that is being investigated in the ongoing FELIX Phase II study of adult relapsed/refractory B-acute lymphocytic leukemia (B-ALL).
[Autolus Therapeutics plc]